mTOR and cancer: many loops in one pathway

被引：339
作者：
Efeyan, Alejo [1 ,2 ]
Sabatini, David M. [1 ,2 ,3 ]
机构：
[1] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA
[2] MIT, Howard Hughes Med Inst, Dept Biol, Cambridge, MA 02139 USA
[3] MIT, Koch Inst Integrat Res Canc, Cambridge, MA 02139 USA
来源：
CURRENT OPINION IN CELL BIOLOGY | 2010年 / 22卷 / 02期
关键词：
PROTEIN-KINASE; CELL-GROWTH; METABOLIC CHECKPOINT; MAMMALIAN TARGET; BINDING PARTNER; RAG GTPASES; COMPLEX; RAPAMYCIN; PHOSPHORYLATION; INHIBITION;
D O I：
10.1016/j.ceb.2009.10.007
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
The mammalian target of rapamycin (mTOR) is a master regulator of cell growth and division that responds to a variety of stimuli, including nutrient, energy, and growth factors. In the last years, a significant number of pieces have been added to the puzzle of how mTOR coordinates and executes its functions. Extensive research on mTOR has also uncovered a complex network of regulatory loops that impact the therapeutic approaches aimed at targeting mTOR.
引用
收藏
页码：169 / 176
页数：8
相关论文
共 58 条
  • [1] PI3K and mTOR inhibitors - a new generation of targeted anticancer agents
    Brachmann, Saskia
    Fritsch, Christine
    Maira, Saveur-Michel
    Garcia-Echeverria, Carlos
    [J]. CURRENT OPINION IN CELL BIOLOGY, 2009, 21 (02) : 194 - 198
  • [2] p53 target genes Sestrin1 and Sestrin2 connect genotoxic stress and mTOR signaling
    Budanov, Andrei V.
    Karin, Michael
    [J]. CELL, 2008, 134 (03) : 451 - 460
  • [3] Carracedo A, 2008, J CLIN INVEST, V118, P3065, DOI [10.1172/JCI34739, 10.1172/jCI34739]
  • [4] Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation
    Choo, Andrew Y.
    Yoon, Sang-Oh
    Kim, Sang Gyun
    Roux, Philippe P.
    Blenis, John
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (45) : 17414 - 17419
  • [5] The tuberous sclerosis complex
    Crino, Peter B.
    Nathanson, Katherine L.
    Henske, Elizabeth Petri
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (13) : 1345 - 1356
  • [6] Characterization of Rictor Phosphorylation Sites Reveals Direct Regulation of mTOR Complex 2 by S6K1
    Dibble, Christian C.
    Asara, John M.
    Manning, Brendan D.
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 2009, 29 (21) : 5657 - 5670
  • [7] Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
    Engelman, Jeffrey A.
    Chen, Liang
    Tan, Xiaohong
    Crosby, Katherine
    Guimaraes, Alexander R.
    Upadhyay, Rabi
    Maira, Michel
    McNamara, Kate
    Perera, Samanthi A.
    Song, Youngchul
    Chirieac, Lucian R.
    Kaur, Ramneet
    Lightbown, Angela
    Simendinger, Jessica
    Li, Timothy
    Padera, Robert F.
    Garcia-Echeverria, Carlos
    Weissleder, Ralph
    Mahmood, Umar
    Cantley, Lewis C.
    Wong, Kwok-Kin
    [J]. NATURE MEDICINE, 2008, 14 (12) : 1351 - 1356
  • [8] Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
    Feldman, Morris E.
    Apsel, Beth
    Uotila, Aino
    Loewith, Robbie
    Knight, Zachary A.
    Ruggero, Davide
    Shokat, Kevan M.
    [J]. PLOS BIOLOGY, 2009, 7 (02) : 371 - 383
  • [9] The regulation of AMPK β1, TSC2, and PTEN expression by p53:: Stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways
    Feng, Zhaohui
    Hu, Wenwei
    de Stanchina, Elisa
    Teresky, Angelika K.
    Jin, Shengkan
    Lowe, Scott
    Levine, Arnold J.
    [J]. CANCER RESEARCH, 2007, 67 (07) : 3043 - 3053
  • [10] PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms
    Freeman, DJ
    Li, AG
    Wei, G
    Li, HH
    Kertesz, N
    Lesche, R
    Whale, AD
    Martinez-Diaz, H
    Rozengurt, N
    Cardiff, RD
    Liu, X
    Wu, H
    [J]. CANCER CELL, 2003, 3 (02) : 117 - 130
123456